Gilgamesh Pharmaceuticals has commenced subject dosing in a Phase IIa clinical trial of GM-1020 to treat major depressive disorder (MDD).
This clinical trial aims to evaluate the safety, tolerability, and efficacy of GM-1020 given as single and multiple oral doses.
The study is designed as a randomised, two-part, controlled trial, starting with an initial placebo-controlled crossover phase, followed by a two-week multiple-dose period.
Gilgamesh anticipates that initial data from the Phase IIa trial will be available in the second half of this year.
An orally bioavailable NMDA receptor antagonist, GM-1020 is claimed to enhance upon established NMDA receptor antagonists by combining their quick and strong clinical efficacy with oral dosing and an enhanced safety/tolerability profile.
Gilgamesh founder and CEO Jonathan Sporn said: “Current treatments which block the serotonin transporter can take four to six weeks to show even a limited benefit and have significant and often limiting side effects, including blunted emotions, weight gain, sleep disturbance, and sexual dysfunction.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition to GM-1020, Gilgamesh is advancing another asset, GM-2505, through Phase II trials for MDD.
In March, the company received a substantial boost with a multi-year $14m grant from the US National Institute on Drug Abuse to develop GM-3009, a cardiac-safe ibogaine analogue for treating substance use disorders.
The grant will provide non-dilutive funding to back IND-enabling toxicology studies, GMP manufacturing, and execute Phase I/Ib clinical trials of GM-3009 in healthy volunteers and opioid use disorder patients.
In December 2023, Gilgamesh stated its plans to initiate a Phase IIa trial of GM-2505 in Q1 2024.
